Zeng Yunjian, Mao Yingmin, Shi Zili, Zhou Yuqi, Zhang Lingfang
Department of Interventional Therapy, Tongde Hospital of Zhejiang Province, Hangzhou, China.
J BUON. 2019 Jul-Aug;24(4):1414-1419.
To investigate the therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on hepatitis B virus (HBV)-related liver cancer.
A total of 126 patients with HBV-related liver cancer were selected and divided into observation group (n=63) and control group (n=63). The patients in the control group were treated with transcatheter arterial chemoembolization (TACE) and antiviral therapy, while those in the observation group were treated with 125I seed implantation combined with TACE and antiviral therapy. The therapeutic effect, liver function, serum HBV DNA and tumor marker levels, and changes in Child-Pugh score and Karnofsky performance status (KPS) score before and after treatment were compared between the two groups.
After treatment in the observation group, the serum alanine aminotransferase (ALT), HBV DNA, alpha fetoprotein (AFP) levels and Child-Pugh score were lower than those in the control group, while the KPS score was significantly higher than in the control group (p<0.05). There was no statistically significant difference in the control rate of liver cancer after treatment between the two groups (p>0.05). The remission rate in the observation group was obviously higher than in the control group (p<0.05).
125I seed implantation combined with chemotherapy and antiviral therapy can effectively eliminate HBV DNA, improve liver function, increase quality of life and enhance the therapeutic effect in patients with HBV-related liver cancer, so it is worthy of clinical popularization.
探讨¹²⁵I粒子植入联合化疗及抗病毒治疗对乙型肝炎病毒（HBV）相关肝癌的治疗效果。
选取126例HBV相关肝癌患者，分为观察组（n = 63）和对照组（n = 63）。对照组患者采用经动脉化疗栓塞术（TACE）及抗病毒治疗，观察组患者采用¹²⁵I粒子植入联合TACE及抗病毒治疗。比较两组患者的治疗效果、肝功能、血清HBV DNA及肿瘤标志物水平，以及治疗前后Child-Pugh评分和卡氏功能状态评分（KPS）的变化。
观察组治疗后血清丙氨酸氨基转移酶（ALT）、HBV DNA、甲胎蛋白（AFP）水平及Child-Pugh评分均低于对照组，而KPS评分显著高于对照组（p < 0.05）。两组治疗后肝癌控制率差异无统计学意义（p > 0.05）。观察组缓解率明显高于对照组（p < 0.05）。
¹²⁵I粒子植入联合化疗及抗病毒治疗能有效清除HBV DNA，改善肝功能，提高生活质量，增强HBV相关肝癌患者的治疗效果，值得临床推广。
